GeneHealth - Your precision medicine

Anthrax Disease

Disease Details

Family Health Simplified

Buy Membership

Description: Anthrax is a serious infectious disease caused by the bacterium Bacillus anthracis, affecting both humans and animals through different forms such as cutaneous, inhalation, and gastrointestinal.
Type: Anthrax is an infectious disease caused by the bacterium Bacillus anthracis. It is not a genetic disease and does not involve genetic transmission. Rather, it is acquired through contact with the spores of the bacterium, which can enter the body through skin cuts, inhalation, ingestion, or injection.
Signs And Symptoms: Signs and symptoms of anthrax vary depending on the route of infection:

1. **Cutaneous Anthrax (skin infection)**:
- Raised, itchy bump resembling an insect bite that develops into a painless sore with a black center
- Swelling around the sore
- Possible fever and malaise

2. **Inhalation Anthrax (lung infection)**:
- Fever and chills
- Chest discomfort
- Shortness of breath
- Cough
- Nausea
- Headache
- Sweats (often drenching)
- Extreme tiredness
- Body aches

3. **Gastrointestinal Anthrax (digestive system infection)**:
- Nausea and vomiting (possibly with blood)
- Abdominal pain
- Severe diarrhea (frequently bloody)
- Sore throat and difficulty swallowing

4. **Injection Anthrax (from injecting illegal drugs)**:
- Redness at the injection site (without clear area of black center)
- Significant swelling
- Shock
- Multiple organ failure

In all forms, symptoms typically begin within 1-7 days of exposure, but inhalation anthrax symptoms can take up to 42 days to appear. Early diagnosis and treatment are crucial for effective management.
Prognosis: Cutaneous anthrax is rarely fatal if treated, because the infection area is limited to the skin, preventing the lethal factor, edema factor, and protective antigen from entering and destroying a vital organ. Without treatment, up to 20% of cutaneous skin infection cases progress to toxemia and death.Before 2001, fatality rates for inhalation anthrax were 90%; since then, they have fallen to 45%. People that progress to the fulminant phase of inhalational anthrax nearly always die, with one case study showing a death rate of 97%. Anthrax meningoencephalitis is also nearly always fatal.Gastrointestinal anthrax infections can be treated, but usually result in fatality rates of 25% to 60%, depending upon how soon treatment commences.
Injection anthrax is the rarest form of anthrax, and has only been seen to have occurred in a group of heroin injecting drug users.
Onset: Anthrax is caused by the bacterium Bacillus anthracis. The onset of symptoms varies depending on the route of infection:
1. **Cutaneous (skin):** Symptoms typically appear within 1-7 days after exposure.
2. **Inhalational (lungs):** Symptoms typically appear within a week, but can take up to 2 months.
3. **Gastrointestinal:** Symptoms typically appear within 1-7 days after consuming contaminated food.
4. **Injection:** Symptoms typically appear within 1-10 days.

Symptoms can vary but may include sores, fever, chest discomfort, and abdominal pain, depending on the infection route. There is no "nan" in the description.
Prevalence: Prevalence of anthrax is relatively low in humans, particularly in developed countries, due to vaccinations and regulations in livestock management. Sporadic cases can occur worldwide, often associated with handling infected animals or animal products. It's more common in regions where livestock vaccination isn't routinely performed, such as parts of Africa, Asia, and the Middle East.
Epidemiology: Globally, at least 2,000 cases occur a year.
Intractability: Anthrax is not considered intractable. It can be treated effectively with antibiotics such as ciprofloxacin, doxycycline, and penicillin, especially if treatment is started early. Additionally, there are vaccines available for prevention, primarily used for individuals at high risk of exposure. However, if left untreated, anthrax can be severe and potentially fatal.
Disease Severity: Anthrax can vary in severity depending on the form of infection. There are three main types:

1. **Cutaneous anthrax:** This is the least severe form and is usually treatable with antibiotics if caught early. It causes skin sores and can lead to more severe systemic symptoms if left untreated.

2. **Inhalation anthrax:** This form is more severe and can be fatal if not treated promptly. It begins with flu-like symptoms and can progress to severe respiratory distress and shock.

3. **Gastrointestinal anthrax:** This form occurs after consuming contaminated food. It can cause severe gastrointestinal symptoms and can be fatal if not treated.

Early diagnosis and appropriate antibiotic treatment are critical to improving outcomes.
Healthcare Professionals: Disease Ontology ID - DOID:7427
Pathophysiology: **Pathophysiology of Anthrax Disease:**

Anthrax is caused by the bacterium *Bacillus anthracis*. The pathophysiology involves the following steps:

1. **Spore Inhalation/Ingestion/Contact:**
- Spores enter the body via inhalation, ingestion, or through cuts in the skin.

2. **Spore Activation:**
- Inside the body, the spores germinate into active bacteria.

3. **Toxin Production:**
- The bacteria produce potent toxins: protective antigen (PA), edema factor (EF), and lethal factor (LF).
- PA binds to cell receptors, facilitating the entry of EF and LF into cells.

4. **Edema and Lethal Toxins:**
- EF, an adenylate cyclase, increases intracellular cAMP, leading to fluid accumulation and edema.
- LF, a protease, disrupts cellular signaling, ultimately causing cell death.

5. **Systemic Spread:**
- Bacteria proliferate in lymphatic tissues and spread to the bloodstream, leading to septicemia.
- The release of toxins causes tissue destruction, bleeding, and shock.

6. **Host Immune Response:**
- The immune system responds with inflammation, but severe systemic toxin production can overwhelm the immune defenses.

This combination of bacterial multiplication and toxin effects leads to the clinical manifestations of anthrax, which can range from localized skin ulcerations to severe respiratory distress or gastrointestinal symptoms, depending on the route of entry.
Carrier Status: Anthrax does not have a human carrier status. It is primarily a disease affecting herbivorous animals, and humans typically become infected through direct or indirect contact with infected animals or their products. Human-to-human transmission of anthrax is extremely rare.
Mechanism: The lethality of the anthrax disease is due to the bacterium's two principal virulence factors: the poly-D-glutamic acid capsule, which protects the bacterium from phagocytosis by host neutrophils; and the tripartite protein toxin, called anthrax toxin, consisting of protective antigen (PA), edema factor (EF), and lethal factor (LF). PA plus LF produces lethal toxin, and PA plus EF produces edema toxin. These toxins cause death and tissue swelling (edema), respectively.
To enter the cells, the edema and lethal factors use another protein produced by B. anthracis called protective antigen, which binds to two surface receptors on the host cell. A cell protease then cleaves PA into two fragments: PA20 and PA63. PA20 dissociates into the extracellular medium, playing no further role in the toxic cycle. PA63 then oligomerizes with six other PA63 fragments forming a heptameric ring-shaped structure named a prepore. Once in this shape, the complex can competitively bind up to three EFs or LFs, forming a resistant complex. Receptor-mediated endocytosis occurs next, providing the newly formed toxic complex access to the interior of the host cell. The acidified environment within the endosome triggers the heptamer to release the LF and/or EF into the cytosol. It is unknown how exactly the complex results in the death of the cell.
Edema factor is a calmodulin-dependent adenylate cyclase. Adenylate cyclase catalyzes the conversion of ATP into cyclic AMP (cAMP) and pyrophosphate. The complexation of adenylate cyclase with calmodulin removes calmodulin from stimulating calcium-triggered signaling, thus inhibiting the immune response. To be specific, LF inactivates neutrophils (a type of phagocytic cell) by the process just described so they cannot phagocytose bacteria. Throughout history, lethal factor was presumed to cause macrophages to make TNF-alpha and interleukin 1, beta (IL1B). TNF-alpha is a cytokine whose primary role is to regulate immune cells, as well as to induce inflammation and apoptosis or programmed cell death. Interleukin 1, beta is another cytokine that also regulates inflammation and apoptosis. The overproduction of TNF-alpha and IL1B ultimately leads to septic shock and death. However, recent evidence indicates anthrax also targets endothelial cells that line serous cavities such as the pericardial cavity, pleural cavity, and peritoneal cavity, lymph vessels, and blood vessels, causing vascular leakage of fluid and cells, and ultimately hypovolemic shock and septic shock.
Treatment: Anthrax cannot be spread from person to person, except in the rare case of skin exudates from cutaneous anthrax. However, a person's clothing and body may be contaminated with anthrax spores. Effective decontamination of people can be accomplished by a thorough wash-down with antimicrobial soap and water. Wastewater is treated with bleach or another antimicrobial agent. Effective decontamination of articles can be accomplished by boiling them in water for 30 minutes or longer. Chlorine bleach is ineffective in destroying spores and vegetative cells on surfaces, though formaldehyde is effective. Burning clothing is very effective in destroying spores. After decontamination, there is no need to immunize, treat, or isolate contacts of persons ill with anthrax unless they were also exposed to the same source of infection.
Compassionate Use Treatment: For anthrax, compassionate use treatment involves providing access to investigational drugs or therapies for patients who have no other viable treatment options. This may include the use of:

1. **Raxibacumab**: A monoclonal antibody that neutralizes the toxins produced by Bacillus anthracis.
2. **Obiltoxaximab**: Another monoclonal antibody used for the treatment and prophylaxis of inhalational anthrax.
3. **Anthim** (obiltoxaximab): FDA-approved for inhalational anthrax but could be considered under compassionate use for other forms of the disease if no other treatments are available.

Off-label or experimental treatments may include:

1. **Linezolid**: An antibiotic that can be used off-label for anthrax infections resistant to standard treatments.
2. **Clindamycin**: Another antibiotic used off-label for severe anthrax cases due to its ability to inhibit toxin production.
3. **Ciprofloxacin or Doxycycline**: Though FDA-approved for anthrax, these can be considered experimental when used in combinations or dosing regimens not specifically indicated on the label.
4. **Hyperbaric Oxygen Therapy (HBOT)**: Has been discussed as a potential treatment to improve oxygenation and wound healing in cutaneous anthrax, though it's still considered experimental.

These treatments should always be administered under the guidance of healthcare professionals specialized in infectious diseases.
Lifestyle Recommendations: For anthrax, it is crucial to avoid contact with potentially contaminated animals or animal products, such as hides, wool, or meat. Implementing the following lifestyle recommendations can help reduce the risk:

1. **Vaccination**: People at high risk, such as those working with livestock or in laboratories, should consider getting vaccinated.

2. **Protective Gear**: Use protective clothing, gloves, and masks when handling animal products or working in environments where anthrax spores may be present.

3. **Hygiene Practices**: Regular handwashing with soap and water, especially after handling animals or animal products.

4. **Proper Cooking**: Ensure all meat is thoroughly cooked, as spores can be present in undercooked meat.

5. **Animal Vaccination**: Livestock in areas where anthrax is common should be vaccinated against the disease.

6. **Safe Handling**: Use caution when dealing with sick animals, and immediately report any suspicious symptoms to veterinary or health authorities.

7. **Dispose Properly**: Properly dispose of animal carcasses suspected of anthrax to prevent soil contamination.

Implementing these practices can significantly lower the risk of contracting anthrax.
Medication: Anthrax is typically treated with antibiotics. The most commonly used antibiotics include ciprofloxacin, doxycycline, and in some cases, penicillin. Early diagnosis and prompt initiation of treatment are crucial for effective management.
Repurposable Drugs: There are no well-known repurposable drugs for anthrax specifically listed here. The standard treatment for anthrax generally involves antibiotics such as ciprofloxacin, doxycycline, or penicillin, depending on the form and severity of the infection.
Metabolites: For anthrax disease, notable metabolites produced by the causative agent, Bacillus anthracis, include anthrax toxin components such as protective antigen (PA), lethal factor (LF), and edema factor (EF). These toxins disrupt cellular functions and contribute to the pathogenicity of the disease. Some non-specific metabolic by-products might also be present due to the bacterial activity, but PA, LF, and EF are the primary metabolic factors directly linked to anthrax's virulence. The notation "nan" suggests that no additional notable metabolites are specified in your query.
Nutraceuticals: Nutraceuticals are products derived from food sources that provide health benefits beyond basic nutrition. However, there is limited evidence supporting the use of nutraceuticals in the prevention or treatment of anthrax. Standard treatment for anthrax involves antibiotics such as ciprofloxacin, doxycycline, or penicillin, and in some cases, antitoxins.

"NAN" generally stands for "Not a Number" and is not relevant in the context of anthrax disease. If you require more specific information or another context for "nan," please specify.
Peptides: Anthrax disease is caused by the bacterium Bacillus anthracis. Peptides, especially those derived from the protective antigen (PA), lethal factor (LF), and edema factor (EF), are significant in developing vaccines and diagnostics for anthrax. These peptides can help elicit an immune response to provide protection against the disease. There is no established connection between "nan" and anthrax disease in the context provided. If "nan" refers to "nanoparticles," research is being conducted to use nanoparticles to enhance vaccine delivery and efficacy.